Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers

This study is testing a personalized cell therapy called CAR-T cell therapy for people with advanced cancers that express certain proteins (Mesothelin, GPC3, or GUCY2C). The patient's own immune cells are taken, re-engineered in the lab to recognize and attack cancer cells, then infused back into the body. This approach is being studied for several hard-to-treat cancers. **You may be eligible if:** - You have an advanced cancer that tests positive for the Mesothelin protein - You are expected to live at least 12 weeks - Your heart, lungs, liver, kidneys, and blood counts are in adequate condition - The re-engineered T cells made from your own blood meet the required quality standards - You or your guardian can give informed consent **You may NOT be eligible if:** - You have previously received gene therapy - Your blood cell counts or organ function are too low to safely undergo this treatment Talk to your doctor to see if this trial is right for you.